title: Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.
abstract: The prevalence of human cytomegalovirus (HCMV) pp65-, pp150-, IE1-exon4-, gB- and pp28-specific cytotoxic T lymphocyte (CTL) responses was compared among 34 healthy individuals, grouped by neutralizing antibody titers. Moderately and highly seropositive donors showed predominantly pp65- and IE1-exon4-specific CTL responses (92% and 76% of the donors, respectively), with similar precursor frequencies in the 2 donors tested. In addition, highly seropositive and a few moderately seropositive donors showed CTL responses to gB and pp150 (33% and 30% of the donors, respectively). No individual recognized pp28 as a target in the CTL assay. Phenotypic analysis revealed a mixed effector population of CD4+ and CD8+ (1 donor) or only CD8+ cells for pp65-specific effectors (2 donors). IE1-exon4- and pp150-specific effectors were CD8+ (2 donors and 1 donor, respectively), whereas gB-specific CTLs were CD4+ (1 donor). These data may help to design a cellular immunity-based vaccine effective against HCMV diseases.
authors.affiliation: Department of Medical Microbiology and South Hungarian Regional Blood Bank of National Transfusion Service, Albert Szent-Gyorgyi University, Szeged, Hungary.
authors.forename: Z
authors.initials: Z
authors.lastname: Gyulai
authors.forename: V
authors.initials: V
authors.lastname: Endresz
authors.forename: K
authors.initials: K
authors.lastname: Burian
authors.forename: S
authors.initials: S
authors.lastname: Pincus
authors.forename: J
authors.initials: J
authors.lastname: Toldy
authors.forename: W I
authors.initials: WI
authors.lastname: Cox
authors.forename: C
authors.initials: C
authors.lastname: Meric
authors.forename: S
authors.initials: S
authors.lastname: Plotkin
authors.forename: E
authors.initials: E
authors.lastname: Gönczöl
authors.forename: K
authors.initials: K
authors.lastname: Berencsi
mesh_terms: D000328:Adult; D000956:Antigens, Viral / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology*; D005091:Exons; D006801:Humans; D017874:Immediate-Early Proteins / Q000235:genetics / Q000276:immunology*; D008875:Middle Aged; D010750:Phosphoproteins / Q000276:immunology*; D044469:Racial Groups; D012016:Reference Values; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000821:virology*; D014759:Viral Envelope Proteins / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000276:immunology*; D014764:Viral Proteins / Q000276:immunology*
chemical_list: D000956:Antigens, Viral; C088645:IE1 protein, cytomegalovirus; D017874:Immediate-Early Proteins; D010750:Phosphoproteins; D014759:Viral Envelope Proteins; D014763:Viral Matrix Proteins; D014764:Viral Proteins; C065418:cytomegalovirus matrix protein 65kDa; C040495:glycoprotein B, Simplexvirus; C070746:human cytomegalovirus protein pp28; C056367:pp150 protein, Cytomegalovirus